Adverum Biotechnologies to Participate in the 42nd Annual Cowen Healthcare ConferenceGlobeNewsWire • 02/28/22
Adverum Biotechnologies Appoints Richard Beckman M.D. as Chief Medical OfficerGlobeNewsWire • 02/07/22
Adverum Biotechnologies Appoints Star Seyedkazemi, Pharm.D. as Chief Development OfficerGlobeNewsWire • 01/06/22
Adverum Biotechnologies Granted Orphan Drug Designation by FDA for Gene Therapy Candidate in Preclinical Development for the Treatment of Blue Cone MonochromacyGlobeNewsWire • 01/04/22
Adverum Biotechnologies Provides ADVM-022 Development Update and Anticipated Corporate Milestones for 2022GlobeNewsWire • 12/21/21
Adverum Biotechnologies Appoints Rupert D'Souza, Ph.D., M.B.A. as Chief Financial OfficerGlobeNewsWire • 12/06/21
Moore Kuehn, PLLC Encourages Investors of Adverum Biotechnologies, Inc. to Contact Law FirmNewsfile Corp • 11/30/21
Adverum Presents Clinical Data on ADVM-022 at the American Society of Retina Specialists 39th Annual Scientific MeetingGlobeNewsWire • 10/09/21
Adverum's Single Dose Wet AMD Gene Therapy Shows Robust Two Year Durability, SafetyBenzinga • 10/04/21
Adverum Presents 2-Year OPTIC Data Demonstrating Sustained Durability and Promising Safety Profile from Single Intravitreal Injection of ADVM-022 in Wet AMD Patients Who Previously Required Frequent Anti-VEGF InjectionsGlobeNewsWire • 10/01/21
Adverum to Present Data from ADVM-022 Clinical Trials at Upcoming Medical ConferencesGlobeNewsWire • 09/27/21
Adverum Appoints Global Regulatory Leader Jim Wang, Ph.D., as Senior Vice President, Head of Regulatory AffairsGlobeNewsWire • 08/23/21
Why Adverum Biotechnologies (ADVM) Might Surprise This Earnings SeasonZacks Investment Research • 08/06/21
Adverum Provides Update on ADVM-022 and the INFINITY Trial in Patients with Diabetic Macular EdemaGlobeNewsWire • 07/22/21
Adverum Biotechnologies (ADVM) Moves to Buy: Rationale Behind the UpgradeZacks Investment Research • 06/28/21